Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. March 17, 2011 Via Federal Express and E-Mail...Royalty Agreement and Distribution Agreement • March 28th, 2011 • Celera CORP • Services-commercial physical & biological research
We are writing with respect to the (i) Royalty Agreement (the “Royalty Agreement”), effective as of October 1, 2008, by and between Celera Corporation (“Celera”) and Abbott Laboratories (“Abbott”) and (ii) Distribution Agreement (the “Distribution Agreement”), effective as of October 1, 2008, between Celera and Abbott Molecular Inc. (“AMI”). The Royalty Agreement and the Distribution Agreement are collectively referred to herein as the “Agreements.” Capitalized terms used herein without definition shall have the meaning ascribed thereto in the Agreements.
AMENDED AND RESTATED ROYALTY AGREEMENT AND DISTRIBUTION AGREEMENTRoyalty Agreement and Distribution Agreement • March 31st, 2021 • Brooklyn ImmunoTherapeutics, Inc. • Pharmaceutical preparations • New York
This Amended and Restated Royalty Agreement and Distribution Agreement (this “Agreement”) is entered into as of March 22, 2021 by and between Brooklyn Immunotherapeutics, LLC, a Delaware limited liability company with offices located at Brooklyn Army Terminal, 140 58th Street, Bldg. A, Suite 2100, Brooklyn, NY 11220 (the “Company”), Brooklyn Immunotherapeutics Investors GP LLC, a Delaware limited liability company (“Investors GP”), Brooklyn Immunotherapeutics Investors LP, a Delaware limited partnership (“Investors LP”), and the beneficiary parties listed on Schedule A (“the “Holders”). Each of the Company, Investors GP, Investors LP and the Holders are jointly referred to herein as the “Parties” and each, individually, as a “Party.”
